SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Jennifer Mullin, Muhammed S. Ahmed, Ravi Sharma, Navdeep Upile, Helen Beer, Priya Achar, Suttida Puksuriwong, Francesca Ferrara, Nigel Temperton, Paul McNamara, Teresa Lambe, Sarah C. Gilbert, Qibo Zhang, Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines, Vaccine, 2016, 34, 14, 1688

    CrossRef

  2. 2
    Muhammad S. Ahmed, Laura C. Jacques, Waleed Mahallawi, Francesca Ferrara, Nigel Temperton, Nav Upile, Casey Vaughan, Ravi Sharma, Helen Beer, Katja Hoschler, Paul S. McNamara, Qibo Zhang, Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection, Antiviral Research, 2015, 114, 106

    CrossRef

  3. 3
    Kirsty L. Wilson, Sue D. Xiang, Magdalena Plebanski, Montanide, Poly I:C and nanoparticle based vaccines promote differential suppressor and effector cell expansion: a study of induction of CD8 T cells to a minimal Plasmodium berghei epitope, Frontiers in Microbiology, 2015, 6,

    CrossRef

  4. 4
    Jian Yan, David Weiner, Gene and Cell Therapy, 2015,

    CrossRef

  5. 5
    Beatrice O. Ondondo, The influence of delivery vectors on HIV vaccine efficacy, Frontiers in Microbiology, 2014, 5,

    CrossRef

  6. 6
    Olasumbo L. Ndi, Mary D. Barton, Thiru Vanniasinkam, Adenoviral Vectors in Veterinary Vaccine Development: Potential for Further Development, World Journal of Vaccines, 2013, 03, 03, 111

    CrossRef

  7. 7
    N.P. Aditya, P.G. Vathsala, V. Vieira, R.S.R. Murthy, E.B. Souto, Advances in nanomedicines for malaria treatment, Advances in Colloid and Interface Science, 2013, 201-202, 1

    CrossRef

  8. 8
    Caitlin D. Lemke, Sean M. Geary, Vijaya B. Joshi, Aliasger K. Salem, Antigen-coated poly α-hydroxy acid based microparticles for heterologous prime-boost adenovirus based vaccinations, Biomaterials, 2013, 34, 10, 2524

    CrossRef

  9. 9
    Carmen Elena Gómez, Beatriz Perdiguero, Juan García-Arriaza, Mariano Esteban, Clinical applications of attenuated MVA poxvirus strain, Expert Review of Vaccines, 2013, 12, 12, 1395

    CrossRef

  10. 10
    Sarah C. Gilbert, Clinical development of Modified Vaccinia virus Ankara vaccines, Vaccine, 2013, 31, 39, 4241

    CrossRef

  11. 11
    L. Zhang, B. W. Bridle, L. Chen, J. Pol, D. Spaner, J. E. Boudreau, A. Rosen, J. D. Bassett, B. D. Lichty, J. L. Bramson, Y. Wan, Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8+ T-cell recall responses, Blood, 2013, 121, 13, 2432

    CrossRef

  12. 12
    Anna Gil, Siyuan Shen, Scott Coley, Laura Gibson, Don J Diamond, Shixia Wang, Shan Lu, DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus, Human Vaccines & Immunotherapeutics, 2013, 9, 10, 2120

    CrossRef

  13. 13
    Rajan Guha, Shantanabha Das, June Ghosh, Kshudiram Naskar, Ashok Mandala, Shyam Sundar, Jean Claude Dujardin, Syamal Roy, Heterologous priming–boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani, Vaccine, 2013, 31, 15, 1905

    CrossRef

  14. 14
    Harriet L. Robinson, Non-neutralizing antibodies in prevention of HIV infection, Expert Opinion on Biological Therapy, 2013, 13, 2, 197

    CrossRef

  15. 15
    Daniel O Villarreal, Kendra T Talbott, Daniel K Choo, Devon J Shedlock, David B Weiner, Synthetic DNA vaccine strategies against persistent viral infections, Expert Review of Vaccines, 2013, 12, 5, 537

    CrossRef

  16. 16
    David B. Weiner, Gary J. Nabel, Vaccines, 2013,

    CrossRef

  17. 17
    Hebata Allah Mahgoub, An overview of infectious bursal disease, Archives of Virology, 2012, 157, 11, 2047

    CrossRef

  18. 18
    Ming-Shen Dai, Georges Vassaux, Man Xu, Ren-In You, Yu-Feng Hsieh, Laure-Hélène Ouisse, Kai-Yu Lo, Huey-Kang Sytwu, Tsu-Yi Chao, Early Treg suppression by a listeriolysin-O-expressing E. coli vaccine in heterologous prime–boost vaccination against cancer, Vaccine, 2012, 30, 48, 6903

    CrossRef

  19. You have free access to this content19
    John M. Kirkwood, Lisa H. Butterfield, Ahmad A. Tarhini, Hassane Zarour, Pawel Kalinski, Soldano Ferrone, Immunotherapy of cancer in 2012, CA: A Cancer Journal for Clinicians, 2012, 62, 5
  20. 20
    Arturo Reyes-Sandoval, Christine S Rollier, Anita Milicic, Karolis Bauza, Matthew G Cottingham, Choon-Kit Tang, Matthew D Dicks, Dong Wang, Rhea J Longley, David H Wyllie, Adrian VS Hill, Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity, Molecular Therapy, 2012, 20, 8, 1633

    CrossRef

  21. 21
    Lilin Lai, Sue-Fen Kwa, Pamela A. Kozlowski, David C. Montefiori, Tracy L. Nolen, Michael G. Hudgens, Welkin E. Johnson, Guido Ferrari, Vanessa M. Hirsch, Barbara K. Felber, George N. Pavlakis, Patricia L. Earl, Bernard Moss, Rama Rao Amara, Harriet L. Robinson, SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses, Vaccine, 2012, 30, 9, 1737

    CrossRef

  22. You have free access to this content22
    Sarah C. Gilbert, T-cell-inducing vaccines – what’s the future, Immunology, 2012, 135, 1
  23. 23
    Chintan Chhatbar, Ritu Mishra, Ashish Kumar, Sunit Kumar Singh, HIV vaccine: hopes and hurdles, Drug Discovery Today, 2011, 16, 21-22, 948

    CrossRef

  24. 24
    Paweena Rattanasena, Itaru Anraku, Joy Gardner, Thuy T Le, Xiang Ju Wang, Alexander A Khromykh, Andreas Suhrbier, Prime-boost vaccinations using recombinant flavivirus replicon and vaccinia virus vaccines: an ELISPOT analysis, Immunology and Cell Biology, 2011, 89, 3, 426

    CrossRef

  25. 25
    Daniela Fioretti, Sandra Iurescia, Vito Michele Fazio, Monica Rinaldi, DNA Vaccines: Developing New Strategies against Cancer, Journal of Biomedicine and Biotechnology, 2010, 2010, 1

    CrossRef

  26. 26
    Hidenobu Ishizaki, Guang-Yun Song, Tumul Srivastava, Kyla Driscoll Carroll, Vafa Shahabi, Edwin R. Manuel, Don J. Diamond, Joshua D.I. Ellenhorn, Heterologous Prime/Boost Immunization With p53-based Vaccines Combined With Toll-like Receptor Stimulation Enhances Tumor Regression, Journal of Immunotherapy, 2010, 33, 6, 609

    CrossRef

  27. 27
    Sylvie Rusakiewicz, Magalie Dosset, Karine Mollier, Philippe Souque, Pierre Charneau, Simon Wain-Hobson, Pierre Langlade-Demoyen, Olivier Adotévi, Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B*0702 transgenic mice, Vaccine, 2010, 28, 38, 6374

    CrossRef

  28. 28
    Takashi Imai, Jianying Shen, Bin Chou, Xuefeng Duan, Liping Tu, Kohhei Tetsutani, Chikako Moriya, Hidekazu Ishida, Shinjiro Hamano, Chikako Shimokawa, Hajime Hisaeda, Kunisuke Himeno, Involvement of CD8+ T cells in protective immunity against murine blood-stage infection with Plasmodium yoelii 17XL strain, European Journal of Immunology, 2010, 40, 4
  29. 29
    George Krashias, Anna-Katharina Simon, Frank Wegmann, Wai-Ling Kok, Ling-Pei Ho, David Stevens, John Skehel, Jonathan L. Heeney, Amin E. Moghaddam, Quentin J. Sattentau, Potent adaptive immune responses induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer, Vaccine, 2010, 28, 13, 2482

    CrossRef

  30. 30
    Jenny Ho, Yi Huang, Michael K. Danquah, Huanting Wang, Gareth M. Forde, Synthesis of biodegradable polymer–mesoporous silica composite microspheres for DNA prime-protein boost vaccination, European Journal of Pharmaceutical Sciences, 2010, 39, 5, 412

    CrossRef

  31. 31
    Shinya Fukumoto, Yoh Tamaki, Ikuo Igarashi, Hiroshi Suzuki, Xuenan Xuan, Immunogenicity and growth inhibitory efficacy of the prime–boost immunization regime with DNA followed by recombinant vaccinia virus carrying the P29 gene of Babesia gibsoni in dogs, Experimental Parasitology, 2009, 123, 4, 296

    CrossRef

  32. 32
    Jens Wild, Kurt Bieler, Josef Köstler, Marie-Joelle Frachette, Simon Jeffs, Sueli Vieira, Mariano Esteban, Peter Liljeström, Guiseppe Pantaleo, Hans Wolf, Ralf Wagner, Preclinical Evaluation of the Immunogenicity of C-Type HIV-1-Based DNA and NYVAC Vaccines in the Balb/C Mouse Model, Viral Immunology, 2009, 22, 5, 309

    CrossRef

  33. 33
    Daniel P Webster, Jeremy Farrar, Sarah Rowland-Jones, Progress towards a dengue vaccine, The Lancet Infectious Diseases, 2009, 9, 11, 678

    CrossRef

  34. 34
    Jayne C. Hope, Bernardo Villarreal-Ramos, Bovine TB and the development of new vaccines, Comparative Immunology, Microbiology and Infectious Diseases, 2008, 31, 2-3, 77

    CrossRef

  35. 35
    Vinod Bhaskara Pillai, Michael Hellerstein, Tianwei Yu, Rama Rao Amara, Harriet L. Robinson, Comparative studies on in vitro expression and in vivo immunogenicity of supercoiled and open circular forms of plasmid DNA vaccines, Vaccine, 2008, 26, 8, 1136

    CrossRef

  36. 36
    Michel Adamina, Walter P. Weber, Rachel Rosenthal, Reto Schumacher, Paul Zajac, Ulrich Guller, Daniel M. Frey, Daniel Oertli, Markus Zuber, Michael Heberer, Giulio C. Spagnoli, Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial, Contemporary Clinical Trials, 2008, 29, 2, 165

    CrossRef

  37. 37
    M. SEDEGAH, W. W. WEISS, S. L. HOFFMAN, Cross-protection between attenuated Plasmodium berghei and P. yoelii sporozoites, Parasite Immunology, 2007, 29, 11
  38. 38
    L. Buonaguro, C. Devito, M.L. Tornesello, U. Schröder, B. Wahren, J. Hinkula, F.M. Buonaguro, DNA–VLP prime–boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity, Vaccine, 2007, 25, 32, 5968

    CrossRef

  39. 39
    Jinyan Liu, Michael Hellerstein, Michael McDonnel, Rama Rao Amara, Linda S. Wyatt, Bernard Moss, Harriet L. Robinson, Dose–response studies for the elicitation of CD8 T cells by a DNA vaccine, used alone or as the prime for a modified vaccinia Ankara boost, Vaccine, 2007, 25, 15, 2951

    CrossRef

  40. 40
    Heiner Voigt, Catherine Merant, Daniel Wienhold, Angelika Braun, Evelyne Hutet, Marie-Frédérique Le Potier, Armin Saalmüller, Eberhard Pfaff, Mathias Büttner, Efficient priming against classical swine fever with a safe glycoprotein E2 expressing Orf virus recombinant (ORFV VrV-E2), Vaccine, 2007, 25, 31, 5915

    CrossRef

  41. 41
    H L Robinson, HIV/AIDS Vaccines: 2007, Clinical Pharmacology & Therapeutics, 2007, 82, 6
  42. 42
    Richard J. Anderson, Joerg Schneider, Plasmid DNA and viral vector-based vaccines for the treatment of cancer, Vaccine, 2007, 25, B24

    CrossRef

  43. 43
    Michel Adamina, Reto Schumacher, Paul Zajac, Walter P. Weber, Rachel Rosenthal, Célia Groeper, Chantal Feder, Rinaldo Zurbriggen, Mario Amacker, Giulio C. Spagnoli, Daniel Oertli, Michael Heberer, Advanced Liposomal Vectors as Cancer Vaccines in Melanoma Immunotherapy, Journal of Liposome Research, 2006, 16, 3, 195

    CrossRef

  44. 44
    Michel Adamina, Ulrich Guller, Laura Bracci, Michael Heberer, Giulio C Spagnoli, Reto Schumacher, Clinical applications of virosomes in cancer immunotherapy, Expert Opinion on Biological Therapy, 2006, 6, 11, 1113

    CrossRef

  45. 45
    M.J. Mulligan, N.D. Russell, C. Celum, J. Kahn, E. Noonan, D.C. Montefiori, G. Ferrari, K.J. Weinhold, J.M. Smith, R.R. Amara, H.L. Robinson, Excellent Safety and Tolerability of the Human Immunodeficiency Virus Type 1 pGA2/JS2 Plasmid DNA Priming Vector Vaccine in HIV Type 1 Uninfected Adults, AIDS Research and Human Retroviruses, 2006, 22, 7, 678

    CrossRef

  46. 46
    A.N. FIANDER, A.J. TRISTRAM, E.J. DAVIDSON, A.E. TOMLINSON, S. MAN, P.J. BALDWIN, J.C. STERLING, H.C. KITCHENER, Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial, International Journal of Gynecological Cancer, 2006, 16, 3
  47. 47
    H.M. Vordermeier, M.A. Chambers, B.M. Buddle, J.M. Pollock, R.G. Hewinson, Progress in the development of vaccines and diagnostic reagents to control tuberculosis in cattle, The Veterinary Journal, 2006, 171, 2, 229

    CrossRef

  48. 48
    S. P. Graham, R. Pelle, Y. Honda, D. M. Mwangi, N. J. Tonukari, M. Yamage, E. J. Glew, E. P. de Villiers, T. Shah, R. Bishop, E. Abuya, E. Awino, J. Gachanja, A. E. Luyai, F. Mbwika, A. M. Muthiani, D. M. Ndegwa, M. Njahira, J. K. Nyanjui, F. O. Onono, J. Osaso, R. M. Saya, C. Wildmann, C. M. Fraser, I. Maudlin, M. J. Gardner, S. P. Morzaria, S. Loosmore, S. C. Gilbert, J.-C. Audonnet, P. van der Bruggen, V. Nene, E. L. N. Taracha, Theileria parva candidate vaccine antigens recognized by immune bovine cytotoxic T lymphocytes, Proceedings of the National Academy of Sciences, 2006, 103, 9, 3286

    CrossRef

  49. 49
    Giulio C. Spagnoli, Michel Adamina, Martin Bolli, Walter P. Weber, Paul Zajac, Walter Marti, Daniel Oertli, Michael Heberer, Felix Harder, Active Antigen-specific Immunotherapy of Melanoma: from Basic Science to Clinical Investigation, World Journal of Surgery, 2005, 29, 6, 692

    CrossRef

  50. 50
    Katrin Schwarz, Edwin Meijerink, Daniel E. Speiser, Alain C. Tissot, Indulis Cielens, Regina Renhof, Andris Dishlers, Paul Pumpens, Martin F. Bachmann, Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles, European Journal of Immunology, 2005, 35, 3
  51. 51
    Jun-Ichi Imoto, Eiji Konishi, Needle-Free Jet Injection of a Mixture of Japanese Encephalitis DNA and Protein Vaccines: A Strategy to Effectively Enhance Immunogenicity of the DNA Vaccine in a Murine Model, Viral Immunology, 2005, 18, 1, 205

    CrossRef

  52. 52
    Harriet L Robinson, Rama Rao Amara, T cell vaccines for microbial infections, Nature Medicine, 2005, 11, 4s, S25

    CrossRef

  53. 53
    Hansi J. Dean, Joel Haynes, Connie Schmaljohn, The role of particle-mediated DNA vaccines in biodefense preparedness, Advanced Drug Delivery Reviews, 2005, 57, 9, 1315

    CrossRef

  54. 54
    Jayne C Hope, H Martin Vordermeier, Vaccines for bovine tuberculosis: current views and future prospects, Expert Review of Vaccines, 2005, 4, 6, 891

    CrossRef

  55. 55
    John E. Herrmann, Harriet L. Robinson, Mucosal Immunology, 2005,

    CrossRef

  56. 56
    Earl L. Parr, Margaret B. Parr, Mucosal Immunology, 2005,

    CrossRef

  57. 57
    E. Prieur, S. C. Gilbert, J. Schneider, A. C. Moore, E. G. Sheu, N. Goonetilleke, K. J. H. Robson, A. V. S. Hill, A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses, Proceedings of the National Academy of Sciences, 2004, 101, 1, 290

    CrossRef

  58. 58
    James M. Smith, Rama Rao Amara, David Campbell, Yan Xu, Milloni Patel, Sunita Sharma, Salvatore T. Butera, Dennis L. Ellenberger, Hong Yi, Lakshmi Chennareddi, James G. Herndon, Linda S. Wyatt, David Montefiori, Bernard Moss, Harold M. McClure, Harriet L. Robinson, DNA/MVA Vaccine for HIV Type 1: Effects of Codon-Optimization and the Expression of Aggregates or Virus-Like Particles on the Immunogenicity of the DNA Prime, AIDS Research and Human Retroviruses, 2004, 20, 12, 1335

    CrossRef

  59. 59
    E.J Davidson, R.L Faulkner, P Sehr, M Pawlita, L.J.C Smyth, D.J Burt, A.E Tomlinson, J Hickling, H.C Kitchener, P.L Stern, Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7), Vaccine, 2004, 22, 21-22, 2722

    CrossRef

  60. 60
    Mary K. Collins, Vincenzo Cerundolo, Gene therapy meets vaccine development, Trends in Biotechnology, 2004, 22, 12, 623

    CrossRef

  61. 61
    Graham Simmons, Anee Lee, Andrew J. Rennekamp, Xin Fan, Paul Bates, Hao Shen, Identification of murine T-cell epitopes in Ebola virus nucleoprotein, Virology, 2004, 318, 1, 224

    CrossRef

  62. 62
    Vasee S Moorthy, Michael F Good, Adrian VS Hill, Malaria vaccine developments, The Lancet, 2004, 363, 9403, 150

    CrossRef

  63. 63
    James M. Smith, Rama Rao Amara, Harold M. McClure, Milloni Patel, Sunita Sharma, Hong Yi, Lakshmi Chennareddi, James G. Herndon, Salvatore T. Butera, Walid Heneine, Dennis L. Ellenberger, Bharat Parekh, Patricia L. Earl, Linda S. Wyatt, Bernard Moss, Harriet L. Robinson, Multiprotein HIV Type 1 Clade B DNA/MVA Vaccine: Construction, Safety, and Immunogenicity in Macaques, AIDS Research and Human Retroviruses, 2004, 20, 6, 654

    CrossRef

  64. 64
    Joel R Haynes, Particle-mediated DNA vaccine delivery to the skin, Expert Opinion on Biological Therapy, 2004, 4, 6, 889

    CrossRef

  65. 65
    Anne C. Moore, Adrian V. S. Hill, Progress in DNA-based heterologous prime-boost immunization strategies for malaria, Immunological Reviews, 2004, 199, 1
  66. 66
    C.C. Breathnach, R. Rudersdorf, D.P. Lunn, Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination, Veterinary Immunology and Immunopathology, 2004, 98, 3-4, 127

    CrossRef

  67. 67
    Anita Gamvrellis, David Leong, Jennifer C. Hanley, Sue D. Xiang, Patricia Mottram, Magdalena Plebanski, Vaccines that facilitate antigen entry into dendritic cells, Immunology and Cell Biology, 2004, 82, 5, 506

    CrossRef

  68. 68
    NICOLA E. COLLINS, ALRI PRETORIUS, MIRINDA KLEEF, KELLY A. BRAYTON, ERICH ZWEYGARTH, BASIL A. ALLSOPP, Development of Improved Vaccines for Heartwater, Annals of the New York Academy of Sciences, 2003, 990, 1
  69. 69
    Gonzalo J. Domingo, Antonella Caivano, Rossella Sartorius, Pasquale Barba, Malin Bäckström, Dominique Piatier-Tonneau, John Guardiola, Piergiuseppe De Berardinis, Richard N. Perham, Induction of specific T-helper and cytolytic responses to epitopes displayed on a virus-like protein scaffold derived from the pyruvate dehydrogenase multienzyme complex, Vaccine, 2003, 21, 13-14, 1502

    CrossRef

  70. 70
    Robert A. Seder, John R. Mascola, The Vaccine Book, 2003,

    CrossRef

  71. 71
    Rama Rao Amara, Harriet L Robinson, A new generation of HIV vaccines, Trends in Molecular Medicine, 2002, 8, 10, 489

    CrossRef

  72. 72
    Bartek Zuber, Barbro Mäkitalo, Anne Kjerrström Zuber, Britta Wahren, A novel potent strategy for induction of immunity to HIV-1 reverse transcriptase in primates, AIDS, 2002, 16, 13, 1839

    CrossRef

  73. 73
    E.M. Agger, P. Andersen, A novel TB vaccine; towards a strategy based on our understanding of BCG failure, Vaccine, 2002, 21, 1-2, 7

    CrossRef

  74. 74
    L López-Fuertes, E Pérez-Jiménez, A.J Vila-Coro, F Sack, S Moreno, S.A Konig, C Junghans, B Wittig, M Timón, M Esteban, DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice, Vaccine, 2002, 21, 3-4, 247

    CrossRef

  75. 75
    N.J. Temperton, DNA vaccines against cytomegalovirus: current progress, International Journal of Antimicrobial Agents, 2002, 19, 3, 169

    CrossRef

  76. 76
    Lukas C. Heukamp, Thorbald van Hall, Ferry Ossendorp, Joy M. Burchell, Cornelis J. M. Melief, Joyce Taylor-Papadimitriou, Rienk Offringa, Effective Immunotherapy of Cancer in MUC1-Transgenic Mice Using Clonal Cytotoxic T Lymphocytes Directed Against an Immunodominant MUC1 Epitope, Journal of Immunotherapy, 2002, 25, 1, 46

    CrossRef

  77. 77
    Sarah C Gilbert, Jörg Schneider, Carolyn M Hannan, Jiang Ting Hu, Magdalena Plebanski, Robert Sinden, Adrian V.S Hill, Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime–boost immunisation regimes, Vaccine, 2002, 20, 7-8, 1039

    CrossRef

  78. 78
    L. Salleras, Tecnologías de producción de vacunas (III). Vacunas génicas, Vacunas, 2002, 3, 4, 145

    CrossRef

  79. 79
    Harriet L. Robinson, VACCINES: NEW HOPE FOR AN AIDS VACCINE, Nature Reviews Immunology, 2002, 2, 4, 239

    CrossRef

  80. 80
    Harriet Robinson, AIDS Vaccine Research, 2002,

    CrossRef

  81. 81
    Fidel Zavala, Mauricio Rodrigues, Dolores Rodriguez, Juan Ramón Rodriguez, Ruth S. Nussenzweig, Mariano Esteban, A Striking Property of Recombinant Poxviruses: Efficient Inducers of in Vivo Expansion of Primed CD8+ T Cells, Virology, 2001, 280, 2, 155

    CrossRef

  82. 82
    AK Sharma, GK Khuller, DNA vaccines: Future strategies and relevance to intracellular pathogens, Immunology and Cell Biology, 2001, 79, 6, 537

    CrossRef

  83. 83
    Denise L Doolan, Stephen L Hoffman, DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation, International Journal for Parasitology, 2001, 31, 8, 753

    CrossRef

  84. 84
    R. Wang, J. Epstein, F. M. Baraceros, E. J. Gorak, Y. Charoenvit, D. J. Carucci, R. C. Hedstrom, N. Rahardjo, T. Gay, P. Hobart, R. Stout, T. R. Jones, T. L. Richie, S. E. Parker, D. L. Doolan, J. Norman, S. L. Hoffman, Induction of CD4+ T cell-dependent CD8+ type 1 responses in humans by a malaria DNA vaccine, Proceedings of the National Academy of Sciences, 2001, 98, 19, 10817

    CrossRef

  85. 85
    Carl G Feng, Tom J Blanchard, Geoffrey L Smith, Adrian VS Hill, Warwick J Britton, Induction of CD8+ T-lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus, Immunology and Cell Biology, 2001, 79, 6, 569

    CrossRef

  86. 86
    Hans Mollenkopf, Guido Dietrich, Stefan H. E. Kaufmann, Intracellular Bacteria as Targets and Carriers for Vaccination, Biological Chemistry, 2001, 382, 4

    CrossRef

  87. 87
    L. Latimer, R. Rankin, L. A. Babiuk, B. I. Loehr, S. van Drunen Littel-van den Hurk, R. Pontarollo, P. Willson, Priming by DNA immunization augments T-cell responses induced by modified live bovine herpesvirus vaccine, Journal of General Virology, 2001, 82, 12, 3035

    CrossRef

  88. 88
    Moriya Tsuji, Elaine G. Rodrigues, Ruth S. Nussenzweig, Progress toward a Malaria Vaccine: Efficient Induction of Protective Anti-Malaria Immunity, Biological Chemistry, 2001, 382, 4

    CrossRef

  89. 89
    Rosa María Gonzalo, Juan Ramón Rodríguez, Dolores Rodríguez, Gloria González-Aseguinolaza, Vicente Larraga, Mariano Esteban, Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36, Microbes and Infection, 2001, 3, 9, 701

    CrossRef

  90. 90
    A Heath, Recent advances in vaccinology, Current Opinion in Pharmacology, 2001, 1, 4, 425

    CrossRef

  91. 91
    Tatyana M. Timiryasova, Bing Chen, Istvan Fodor, Replication-deficient vaccinia virus gene therapy vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells, The Journal of Gene Medicine, 2001, 3, 5
  92. 92
    Tim H Scott-Taylor, Angus G Dalgleish, DNA vaccines, Expert Opinion on Investigational Drugs, 2000, 9, 3, 471

    CrossRef

  93. 93
    Magdalena Plebanski, Adrian VS Hill, The immunology of malaria infection, Current Opinion in Immunology, 2000, 12, 4, 437

    CrossRef

  94. 94
    T. Mark Doherty, Peter Andersen, Tuberculosis vaccines: developmental work and the future, Current Opinion in Pulmonary Medicine, 2000, 6, 3, 203

    CrossRef

  95. 95
    Harriet L Robinson, Tamera M Pertmer, 2000,

    CrossRef

  96. 96
    Gene Transfer with Plasmid Biopharmaceuticals,